Matches in SemOpenAlex for { <https://semopenalex.org/work/W3128694802> ?p ?o ?g. }
- W3128694802 endingPage "119018" @default.
- W3128694802 startingPage "119018" @default.
- W3128694802 abstract "Diabetic nephropathy is a major cause of chronic kidney disease and end-stage renal failure worldwide. Dapagliflozin Sodium-glucose co-transporter 2 (SGLT2) inhibitor is a new class of diabetic medications prescribed for the treatment of type 2 diabetes. The current study investigates the possible impact of dapagliflozin (DAPA) on inflammations, apoptosis, angiogenesis and fibrosis in early-stage diabetic nephropathy using a rat model of type 2 diabetes. Rats were divided into five groups, group1: normal vehicle group, group 2: diabetic group, group 3: diabetic+ DAPA (0.75 mg/kg), group 4: diabetic+DAPA (1.5 mg/kg), group 5: diabetic+DAPA (3 mg/kg). At the end of the study, Blood glucose level was measured. Serum insulin, BUN, and SCr were measured. Insulin resistance was determined using the homeostasis model assessment for insulin resistance (HOMA-IR) index. Renal tissue homogenization was done for assessment of inflammatory markers TNF-α, PEDF, and PTX-3, In addition to apoptosis markers BCL-2 and BAX. Histopathological examinations were done for tubular renal cells and immunohistochemical examination for fibrosis marker α-SMA and angiogenic factor VEGF. Treatments with dapagliflozin showed improvements in histopathological examinations, inflammatory and apoptotic markers compared to diabetic vehicles in a dose-dependent manner. Thus, dapagliflozin may have renoprotective effects, which be promising in diabetic patients suffered from nephropathy." @default.
- W3128694802 created "2021-02-15" @default.
- W3128694802 creator A5000558204 @default.
- W3128694802 creator A5009982081 @default.
- W3128694802 creator A5036019638 @default.
- W3128694802 creator A5082606593 @default.
- W3128694802 date "2021-09-01" @default.
- W3128694802 modified "2023-10-09" @default.
- W3128694802 title "Role of sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats; Inflammation, angiogenesis and apoptosis" @default.
- W3128694802 cites W1579574489 @default.
- W3128694802 cites W1752094483 @default.
- W3128694802 cites W1888211049 @default.
- W3128694802 cites W1950586730 @default.
- W3128694802 cites W1959095543 @default.
- W3128694802 cites W1970241511 @default.
- W3128694802 cites W1972892003 @default.
- W3128694802 cites W1978701013 @default.
- W3128694802 cites W1979541659 @default.
- W3128694802 cites W1982173050 @default.
- W3128694802 cites W1986025060 @default.
- W3128694802 cites W1999647741 @default.
- W3128694802 cites W2007117103 @default.
- W3128694802 cites W2018324845 @default.
- W3128694802 cites W2041531589 @default.
- W3128694802 cites W2051616579 @default.
- W3128694802 cites W2053075493 @default.
- W3128694802 cites W2082972908 @default.
- W3128694802 cites W2093840384 @default.
- W3128694802 cites W2104039648 @default.
- W3128694802 cites W2107277218 @default.
- W3128694802 cites W2108192985 @default.
- W3128694802 cites W2112150914 @default.
- W3128694802 cites W2121611290 @default.
- W3128694802 cites W2129367672 @default.
- W3128694802 cites W2150796310 @default.
- W3128694802 cites W2157871856 @default.
- W3128694802 cites W2159929147 @default.
- W3128694802 cites W2160234571 @default.
- W3128694802 cites W2166602064 @default.
- W3128694802 cites W2167245776 @default.
- W3128694802 cites W2171786511 @default.
- W3128694802 cites W2318779348 @default.
- W3128694802 cites W2466230370 @default.
- W3128694802 cites W2540977893 @default.
- W3128694802 cites W2582024076 @default.
- W3128694802 cites W2593682661 @default.
- W3128694802 cites W2620604536 @default.
- W3128694802 cites W2757385123 @default.
- W3128694802 cites W2772154846 @default.
- W3128694802 cites W2788733974 @default.
- W3128694802 cites W2797320481 @default.
- W3128694802 cites W2803513068 @default.
- W3128694802 cites W2810698005 @default.
- W3128694802 cites W2870743986 @default.
- W3128694802 cites W2883722299 @default.
- W3128694802 cites W2885290355 @default.
- W3128694802 cites W2921866736 @default.
- W3128694802 cites W2939048096 @default.
- W3128694802 cites W2946078715 @default.
- W3128694802 cites W2953132927 @default.
- W3128694802 cites W2974007467 @default.
- W3128694802 cites W2999431040 @default.
- W3128694802 cites W3000815364 @default.
- W3128694802 cites W3004458192 @default.
- W3128694802 cites W3009705249 @default.
- W3128694802 cites W3019674116 @default.
- W3128694802 cites W3025320509 @default.
- W3128694802 cites W3027192532 @default.
- W3128694802 cites W3032460799 @default.
- W3128694802 cites W3042519842 @default.
- W3128694802 cites W3080940809 @default.
- W3128694802 cites W3094257978 @default.
- W3128694802 doi "https://doi.org/10.1016/j.lfs.2021.119018" @default.
- W3128694802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33549594" @default.
- W3128694802 hasPublicationYear "2021" @default.
- W3128694802 type Work @default.
- W3128694802 sameAs 3128694802 @default.
- W3128694802 citedByCount "28" @default.
- W3128694802 countsByYear W31286948022021 @default.
- W3128694802 countsByYear W31286948022022 @default.
- W3128694802 countsByYear W31286948022023 @default.
- W3128694802 crossrefType "journal-article" @default.
- W3128694802 hasAuthorship W3128694802A5000558204 @default.
- W3128694802 hasAuthorship W3128694802A5009982081 @default.
- W3128694802 hasAuthorship W3128694802A5036019638 @default.
- W3128694802 hasAuthorship W3128694802A5082606593 @default.
- W3128694802 hasConcept C126322002 @default.
- W3128694802 hasConcept C134018914 @default.
- W3128694802 hasConcept C2777180221 @default.
- W3128694802 hasConcept C2777391703 @default.
- W3128694802 hasConcept C2777422806 @default.
- W3128694802 hasConcept C2778653478 @default.
- W3128694802 hasConcept C2779922275 @default.
- W3128694802 hasConcept C2780394083 @default.
- W3128694802 hasConcept C2780559512 @default.
- W3128694802 hasConcept C2781184683 @default.
- W3128694802 hasConcept C555293320 @default.
- W3128694802 hasConcept C71924100 @default.